Sotorasib for adenocarcinoma of lung

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Nov 2020: Trial registered, NCT04625647
  2. 16 Apr 2021: Trial started, NCT04625647

The trials

NCT04625647: Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

State
Under way
Phase
Phase 2
People
116 planned
Started
16 Apr 2021
Primary completion
31 Dec 2026
Arms
Treatment (AMG 510)
Results
None posted
  1. 12 Nov 2020: Trial registered
  2. 16 Apr 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Lumakras.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.